All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

pirarubicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antineoplastics, daunorubicin derivatives	2198	72496-41-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: pirarubicin pinorubicin therarubicin	Molecular weight: 627.64 Formula: C32H37NO12 CLOGP: 1.70 LIPINSKI: 2 HAC: 13 HDO: 5 TPSA: 204.30 ALOGS: -3.32 ROTB: 7

Drug dosage:

None

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	43.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	57.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	11.10 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	1.658		Moderate	0.78
caco2-efflux	Caco-2 efflux ratio (BA/AB)	32.137		Moderate	0.78
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	3.776	10^-6 cm/s	Moderate	0.78
dh-clint	Dog hepatocyte intrinsic clearance	3.451	uL/min/10^6 cells	Moderate	0.78
dppb	Dog plasma protein binding (% unbound)	9.940	%	Moderate	0.78
fcs-ppb	Fetal calf serum protein binding (% unbound)	12.480	%	Moderate	0.78
herg	hERG pIC50	4.675	pIC50	Moderate	0.78
hh-clint	Human hepatocyte intrinsic clearance	3.055	uL/min/10^6 cells	Moderate	0.78
hlm-clint	Human liver microsomal intrinsic clearance	9.908	uL/min/mg protein	Moderate	0.78
hppb	Human plasma protein binding (% unbound)	6.500	%	Moderate	0.78
kinase-safety-class	ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,GSK3B,ITK,KDR,MAP2K6,MAP3K7,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1	36
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	26.853		Moderate	0.78
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	17.140		Moderate	0.78
mh-clint	Mouse hepatocyte intrinsic clearance	8.299		Moderate	0.78
mppb	Mouse plasma protein binding (% unbound)	4.910		Moderate	0.78
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	27.479		Moderate	0.78
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	11.320	%	Moderate	0.78
rat-kpuu-brain	Rat brain Kpuu	0.015	%	Moderate	0.78
rh-clint	Rat hepatocyte intrinsic clearance	8.670	uL/min/10^6 cells	Moderate	0.78
rh-fuinc	Rat hepatocyte fraction unbound in incubation	43.590	%	Moderate	0.78
rppb	Rat plasma protein binding (% unbound)	5.490	%	Moderate	0.78
solubility-dd	Solubility at pH 7.4 in DMSO	95.719	uM	Moderate	0.78

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bone marrow failure	208.20	60.67	45	435	32176	90595791
Myelosuppression	190.58	60.67	46	434	53545	90574422

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myelosuppression	73.91	44.89	25	501	40436	42580373
Renal salt-wasting syndrome	50.88	44.89	8	518	408	42620401
Bone marrow failure	50.85	44.89	18	508	33075	42587734

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bone marrow failure	230.82	40.41	62	1032	57786	110530419
Myelosuppression	222.31	40.41	67	1027	94273	110493932
Renal salt-wasting syndrome	46.55	40.41	8	1086	880	110587325
Pleuroparenchymal fibroelastosis	46.05	40.41	7	1087	356	110587849

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01DB08	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES Anthracyclines and related substances
MeSH PA	D000970	Antineoplastic Agents
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:50912	cardiotoxic agent

Related Drugs by ATC class:

L01DB Anthracyclines and related substances 10 drugs

aclarubicinamrubicindaunorubicindoxorubicinepirubicinidarubicinmitoxantronepixantronevalrubicinzorubicin

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.11	acidic
pKa2	9.21	acidic
pKa3	9.92	acidic
pKa4	11.11	acidic
pKa5	7.5	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Histone deacetylase 6	Enzyme	Q9UBN7	HDAC6_HUMAN		IC50	5.90		CHEMBL

External reference:

ID	Source
D01885	KEGG_DRUG
C0071126	UMLSCUI
CHEBI:94770	CHEBI
CHEMBL2354444	ChEMBL_ID
DB11616	DRUGBANK_ID
C027260	MESH_SUPPLEMENTAL_RECORD_UI
5877	INN_ID
D58G680W0G	UNII
11296583	PUBCHEM_CID
33764	RXNORM
005780	NDDF
713434008	SNOMEDCT_US
D58G680W0G	INXIGHT DRUGS

Pharmaceutical products:

None